Dr Reddy's Laboratories announced on Friday that it has signed an agreement with the Japanese pharmaceutical giant Takeda Pharmaceutical. This agreement provides for the promotion and distribution of the dengue vaccine Qdenga in India.
The deal was signed several months after India's regulator approved the use of Qdenga for both children and adults, making this vaccine the first to receive such approval in the country.
According to Dr Reddy's, the Qdenga vaccine is expected to be available in India in the first half of 2027.
Dengue is a mosquito-borne viral disease and is among the fastest-growing vector-borne diseases globally. The World Health Organization reported a record 14.4 million dengue cases and 11,201 deaths worldwide in 2024. Among these figures, there were 232,425 cases and 233 deaths in India.
The Qdenga vaccine is administered in two doses of 0.5 ml, taken three months apart. The vaccine can be used regardless of previous dengue infection, eliminating the need for pre-vaccination screening.


